Parallax Volatility Advisers, L.P. Apellis Pharmaceuticals, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $4.3 Million - $6.13 Million	149,000 New	149,000 $4.3 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $798,510 - $1.39 Million	21,500 Added 346.77%	27,700 $1.66 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $255,419 - $963,576	-10,800 Reduced 63.53%	6,200 $235,000
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $4.72 Million - $5.74 Million	-61,500 Reduced 78.34%	17,000 $1.55 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $218,973 - $314,711	-4,700 Reduced 5.65%	78,500 $5.18 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $3.6 Million - $5.08 Million	83,200 New	83,200 $4.3 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $501,501 - $846,703	-14,300 Reduced 9.53%	135,700 $6.14 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $2.71 Million - $4.13 Million	76,400 Added 103.8%	150,000 $7.62 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.17 Million - $1.87 Million	-38,100 Reduced 34.11%	73,600 $3.48 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $810,120 - $1.8 Million	-25,800 Reduced 18.76%	111,700 $3.68 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $5.62 Million - $8.92 Million	137,500 New	137,500 $8.69 Million
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $667,962 - $868,170	-25,800 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $605,120 - $939,156	24,400 Added 1742.86%	25,800 $843,000
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $30,940 - $43,120	1,400 New	1,400 $43,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.